The only therapy that has demonstrated a direct survival benefit in patients with PAH is intravenous epoprostenol, a prostanoid vasodilator. Epoprostenol improves exercise capacity, hemodynamics, and survival and is effective in PAH related to connective tissue disorders, congenital heart disease, and drug-induced pulmonary hypertension. It is recommended that all patients in intermediate- to high-risk groups be initiated on combination therapy, including a parenteral pulmonary vasodilator for high-risk patients.
Learn more about pulmonary arterial hypertension.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Vikramjit Khangoora. Fast Five Quiz: Pulmonary Arterial Hypertension Treatment - Medscape - Jun 02, 2022.